Global Infrastructure Partners Transition Feeder Fund-B, L.P. has made a significant update regarding its investment offerings. The firm filed an amendment that reveals a total amount sold of approximately $911.6 million. This move is crucial as it showcases the fund's ability to attract capital in a competitive market.
Global Infrastructure Partners Transition Feeder Fund-B, L.P. is classified as a pooled investment fund, specifically a private equity fund. The firm is incorporated in the Cayman Islands and operates from its headquarters located at 50 Hudson Yards, New York, NY. This recent filing, dated November 4, 2026, is an amendment to a previous filing made on the same date in 2025.
The filing indicates that the fund is utilizing Rule 506(b) for its private offering, which provides a "safer harbor" for such investments. It is noteworthy that the total amount sold includes contributions from its related funds, namely Global Infrastructure Partners Transition Fund-A/B, L.P. and Global Infrastructure Partners Transition Fund-C2, SCSp.
As per the filing, the fund has not yet accepted any investments from non-accredited investors, maintaining a focus on accredited individuals and institutions. The total offering amount remains indefinite, suggesting that the fund intends to continue raising capital beyond the current figures reported.
This update may impact various stakeholders, including existing investors, potential investors, and competitors in the private equity industry. The fund's success in raising significant capital could influence market dynamics and investment strategies among its peers.
Looking ahead, the filing does not specify any immediate next steps or future filings related to this amendment. However, the ongoing efforts to secure investments indicate that Global Infrastructure Partners Transition Feeder Fund-B, L.P. is committed to expanding its footprint in the private equity market.
Read Next
HSBC USA Inc offers new investment notes linked to ETF
POMDOCTOR Ltd Converts Debt to Equity in Major Agreement
Quoin Pharmaceuticals Enters Sales Agreement with Leerink
AT Umbrella LLC files new private offering of $1.92 billion
Summit Therapeutics registers 108.96 million shares for resale
GS Finance Corp. unveils new market-linked securities offering








